Is there any role for elacestrant in patient who have received prior fulvestrant if they have ESR1 mutation?

The short answer is Yes!!

The pivotal EMERALD trial that led to the approval of Elacestrant (oral Selective Estrogen Receptor Degrader) did enroll patients who previously received Fulvestrant (Faslodex).

In a pre-planned subgroup analysis of EMERALD data, benefit of Elacestrant was seen even in subg...

The phase III EMERALD trial represented an important paradigm shift for HR+ metastatic breast cancer management (Bidard et al., PMID 35584336). This randomized prospective open-label study enrolled patients with advanced/metastatic HR+/HER2- breast cancer with prior progression on 1-2 endocrine ther...

As pointed out by the other experts, the EMERALD Trial did enroll patients with ESR1 mutation positive HR+/HER2- breast cancer who previously received fulvestrant, and such patients appeared to derive similar benefit from elacestrant as patients who were not previously treated with fulvestrant as no...